Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Hatherill

Showing results (201-210 of 222) with videos related to

Pageof 23
Sort By:
The Journal of Infectious Diseases|April 9, 2020
Peripheral Blood Mucosal-Associated Invariant T Cells in Tuberculosis Patients and Healthy Mycobacterium tuberculosis-Exposed ControlsSara Suliman, Anele Gela, Simon C Mendelsohn, et al.
The Lancet. Infectious Diseases|January 28, 2021
Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trialThomas J Scriba, Andrew Fiore-Gartland, Adam Penn-Nicholson, et al.
The Lancet. Global Health|April 16, 2021
Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy studySimon C Mendelsohn, Andrew Fiore-Gartland, Adam Penn-Nicholson, et al.
The New England Journal of Medicine|October 4, 2018
Phase 2b Controlled Trial of M72/AS01<sub>E</sub> Vaccine to Prevent TuberculosisOlivier Van Der Meeren, Mark Hatherill, Videlis Nduba, et al.
JCI Insight|November 8, 2019
Cytomegalovirus infection is a risk factor for tuberculosis disease in infantsJulius Müller, Rachel Tanner, Magali Matsumiya, et al.
Cell Host & Microbe|June 16, 2017
Antigen Availability Shapes T Cell Differentiation and Function during TuberculosisAlbanus O Moguche, Munyaradzi Musvosvi, Adam Penn-Nicholson, et al.
Scientific Reports|May 27, 2020
RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment responseAdam Penn-Nicholson, Stanley Kimbung Mbandi, Ethan Thompson, et al.
The New England Journal of Medicine|October 30, 2019
Final Analysis of a Trial of M72/AS01<sub>E</sub> Vaccine to Prevent TuberculosisDereck R Tait, Mark Hatherill, Olivier Van Der Meeren, et al.
The Lancet. Respiratory Medicine|December 11, 2020
Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trialTracey A Day, Adam Penn-Nicholson, Angelique Kany Kany Luabeya, et al.
Nature Communications|April 13, 2016
T-cell activation is an immune correlate of risk in BCG vaccinated infantsHelen A Fletcher, Margaret A Snowden, Bernard Landry, et al.
Pageof 23

Showing results (201-210 of 222) with videos related to

Sort By:
Pageof 23
The Journal of Infectious Diseases|April 9, 2020
Peripheral Blood Mucosal-Associated Invariant T Cells in Tuberculosis Patients and Healthy Mycobacterium tuberculosis-Exposed ControlsSara Suliman, Anele Gela, Simon C Mendelsohn, et al.
The Lancet. Infectious Diseases|January 28, 2021
Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trialThomas J Scriba, Andrew Fiore-Gartland, Adam Penn-Nicholson, et al.
The Lancet. Global Health|April 16, 2021
Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy studySimon C Mendelsohn, Andrew Fiore-Gartland, Adam Penn-Nicholson, et al.
The New England Journal of Medicine|October 4, 2018
Phase 2b Controlled Trial of M72/AS01<sub>E</sub> Vaccine to Prevent TuberculosisOlivier Van Der Meeren, Mark Hatherill, Videlis Nduba, et al.
JCI Insight|November 8, 2019
Cytomegalovirus infection is a risk factor for tuberculosis disease in infantsJulius Müller, Rachel Tanner, Magali Matsumiya, et al.
Cell Host & Microbe|June 16, 2017
Antigen Availability Shapes T Cell Differentiation and Function during TuberculosisAlbanus O Moguche, Munyaradzi Musvosvi, Adam Penn-Nicholson, et al.
Scientific Reports|May 27, 2020
RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment responseAdam Penn-Nicholson, Stanley Kimbung Mbandi, Ethan Thompson, et al.
The New England Journal of Medicine|October 30, 2019
Final Analysis of a Trial of M72/AS01<sub>E</sub> Vaccine to Prevent TuberculosisDereck R Tait, Mark Hatherill, Olivier Van Der Meeren, et al.
The Lancet. Respiratory Medicine|December 11, 2020
Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trialTracey A Day, Adam Penn-Nicholson, Angelique Kany Kany Luabeya, et al.
Nature Communications|April 13, 2016
T-cell activation is an immune correlate of risk in BCG vaccinated infantsHelen A Fletcher, Margaret A Snowden, Bernard Landry, et al.
Pageof 23